Compare YELP & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | AVDL |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2012 | 1996 |
| Metric | YELP | AVDL |
|---|---|---|
| Price | $30.83 | $21.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $32.00 | $18.38 |
| AVG Volume (30 Days) | 876.3K | ★ 1.3M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.30 | N/A |
| EPS | ★ 2.25 | N/A |
| Revenue | ★ $1,466,918,000.00 | $248,517,000.00 |
| Revenue This Year | $5.73 | $65.47 |
| Revenue Next Year | $2.81 | $30.88 |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | 5.34 | ★ 79.88 |
| 52 Week Low | $27.29 | $6.38 |
| 52 Week High | $41.72 | $23.57 |
| Indicator | YELP | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 58.29 |
| Support Level | $30.09 | $21.40 |
| Resistance Level | $30.89 | $21.53 |
| Average True Range (ATR) | 0.65 | 0.11 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 48.13 | 46.67 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making better buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.